Lenvima 8 mg

Lenvatinib, the active ingredient in Lenvima 8 mg, is a tyrosine kinase inhibitor presented as an 8 mg capsule for oral use. It is used to treat various forms of advanced cancer, including differentiated thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and endometrial carcinoma. GNH USA supplies Lenvima 8 mg as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA is a trusted supplier of Lenvima 8 mg, ensuring high-quality pharmaceutical products for global markets.

Lenvima 8 mg is a multi-targeted tyrosine kinase inhibitor designed to treat various forms of advanced cancer. It works by blocking multiple signaling pathways responsible for tumor growth, angiogenesis, and cancer cell survival.

- Differentiated thyroid cancer: Used to treat differentiated thyroid cancer that is no longer responding to radioactive iodine treatment. - Hepatocellular carcinoma: Used as a first-line treatment for unresectable hepatocellular carcinoma. - Renal cell carcinoma: Used in combination with everolimus for advanced renal cell carcinoma following prior anti-angiogenic therapy. - Endometrial carcinoma: Used in combination with pembrolizumab for advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR).

Lenvima 8 mg may cause various side effects, ranging from common to serious. Common Side Effects: - Fatigue - Diarrhea - Decreased appetite - Nausea - Vomiting - Hypertension - Protein in the urine - Weight loss - Stomach pain - Headache

Serious or Rare Side Effects: - Severe high blood pressure - Heart problems - Liver problems - Kidney problems - Bleeding - Blood clots - Hole in the stomach or intestines - Thyroid problems - Reversible posterior leukoencephalopathy syndrome (RPLS) - Severe skin reactions

Lenvima 8 mg should be used with caution and under the supervision of a healthcare professional. It is important to follow the prescribed dosage and monitor for any adverse effects. Precautions include: - Blood pressure monitoring: Regularly monitor blood pressure as Lenvima can cause hypertension. - Heart function monitoring: Assess heart function before and during treatment. - Liver function monitoring: Regularly monitor liver function tests. - Kidney function monitoring: Regularly monitor kidney function tests. - Thyroid function monitoring: Regularly monitor thyroid function tests. - Pregnancy: Lenvima should not be used during pregnancy as it can harm the fetus. - Store at room temperature: Keep the medication in its original container, protect it from light and moisture, and keep it out of the reach of children.

Lenvima 8 mg may interact with other medications, which can affect its efficacy or increase the risk of side effects. Major Interactions (Avoid): - Strong CYP3A4 inducers: Avoid concomitant use as they can decrease the concentration of Lenvatinib. - Strong CYP3A4 inhibitors: Avoid concomitant use as they can increase the concentration of Lenvatinib. - Moderate Interactions (Monitor Closely): - Antihypertensive drugs: Monitor blood pressure closely as Lenvima can cause hypertension. - Anticoagulants: Monitor for signs of bleeding as Lenvima can increase the risk of bleeding. - Drugs metabolized by CYP3A4: Monitor for increased or decreased effects as Lenvatinib can affect the metabolism of these drugs.